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Abstract
Background/objectives: Cereal foods are major contributors to the daily energy, protein, and dietary fiber intake
all over the world. The role of cereals in human health is dependent on whether they are consumed as refined or
whole grain and on cereal species. To unravel the underlying mechanisms of health effects attributed to specific
cereal foods and to provide more precise dietary advice, there is a need for improved dietary assessment of whole-
grain intake. Dietary biomarkers of specific cereals, different fractions or cereal-containing foods could offer such a
possibility. The aim of this review was to summarize the current status on biomarkers of different cereals, fractions,
and specific cereal foods.
Subjects and methods: A literature review was conducted and putative biomarkers of different cereals and
pseudo-cereals (wheat, oats, rye, barley, rice, and quinoa) as well as for different grain fractions (whole grain, refined
grain, bran) and foods were summarized and discussed.
Results: Several putative biomarkers have been suggested for different cereals, due to their unique presence in these
grains. Among the biomarkers, odd-numbered alkylresorcinols are the most well-studied and -evaluated biomarkers
and reflect whole-grain wheat and rye intake. Even-numbered alkylresorcinols have been suggested to reflect quinoa
intake. Recent studies have also highlighted the potential of avenanthramides and avenacosides as specific biomarkers
of oat intake, and a set of biomarkers have been suggested to reflect rice bran intake. However, there are yet no
specific biomarkers of refined grains. Most biomarker candidates remain to be evaluated in controlled interventions
and free-living populations before applied as biomarkers of intake in food and health studies.
Conclusion: Several putative biomarkers of different cereals have been suggested and should be validated in human
studies using recently developed food intake biomarker validation criteria.
Keywords: Cereals, Biomarkers, Whole grain, Alkylresorcinols, Cinnamic acids, Phenolic acids, Benzoxazinoids,
Avenanthramides, Avenacosides
Background
Cereal foods constitute a major food group, and they are
one of the main contributors to energy and dietary fiber
intake in the diet all over the world [1]. Today, cereals
are mostly consumed as refined grains, i.e., the nutrient-
rich bran and germ have been removed. However, whole
grain-based foods, i.e., where all parts of the grain kernel
are present in cracked, intact, or milled form, is reaching
wider acceptance among consumers. Whole-grain foods
are advocated by governmental authorities in many
countries due to beneficial health effects [2]. Whole-
grain food intake has been consistently associated with
lower risk of non-communicable diseases such as obes-
ity, cardiovascular disease, type 2 diabetes, and colorectal
cancer in different populations [3–7], whereas a high in-
take of refined grains has been associated with no or
even adverse health outcomes [4, 8, 9]. Whole grains are
rich in dietary fiber, vitamins, minerals, unsaturated fatty
acids, and phytochemicals, all of which may contribute
to protective effects [10]. Moreover, the native structure
of the food raw material as well as process induced
structural changes that might encapsulate nutrients, slow
digestion, and absorption could also play a role for
health especially in the gut [11]. Specific dietary fibers,
such as β-glucans, the fructans, and resistant starches,
including process-induced resistant starch commonly
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found in whole grains, could induce gut microbiota fer-
mentation in the large intestine, which has been linked
to beneficial health effects [12, 13].
While observational studies [3–5, 14, 15] have provided
consistent evidence for a beneficial effect of high whole-
grain intake in chronic disease prevention, the outcomes
from short- to long-term randomized controlled trials are
less consistent [16, 17]. Yet, randomized controlled trials
investigating the role of whole-grain intake for primary
prevention of non-communicable disease have not been
reported, due to large challenges related to costs of such
trials and problems to ensure compliance over long pe-
riods of time. Instead, short-term dietary interventions to
address effects on established biomarkers or risk markers
for non-communicable diseases have been conducted to
investigate the role of separate grains and mixed whole
grains on cardiometabolic risk factors, but also short- to
intermediate-term studies have been shown to have prob-
lems with compliance [17–19].
A problem in observational studies is that whole-grain
intake is associated with an overall healthy lifestyle and
dietary pattern, and it is difficult to study the impact of
whole grains per se on health outcomes, despite adjust-
ment for confounding factors [20]. Moreover, and prob-
ably more importantly, the dietary instruments typically
used to assess whole-grain intake in observational stud-
ies lack the precision required to accurately measure the
intake of different grains separately. Various cereals dif-
fer in the content and composition of constituents
thought to exert health effects, but this has typically not
been accounted for in observational studies [21–23]. An-
other challenge for accurate assessment of the habitual
whole-grain intake with common self-reporting tech-
niques such as food frequency questionnaires, dietary re-
calls, or food records is that consumers may have
difficulties in distinguishing/identifying different grains
and to understand portion sizes, in addition to well-
known effects of under- and over-reporting. Furthermore,
whole-grain products have a large variation in whole-grain
content, which affects the precision of estimates [24].
Moreover, no uniform definition of whole-grain products
or serving size has been used across studies [25–27]. This
may lead to misclassification, which is likely to attenuate
the association between whole grain and disease towards
null and preventing existing associations with disease out-
comes to be revealed or cause underestimation of associa-
tions that may be stronger than observed [28].
Using dietary biomarkers that reflect the intake of spe-
cific whole grains, grain fractions, and refined grains could
be a strategy to improve whole-grain intake ranking in ob-
servational studies as well as to address compliance in
dietary intervention studies [29–32]. Dietary biomarkers
may also be combined with traditional methods to im-
prove the accuracy of intake estimations [33]. However,
only a few dietary biomarkers that reflect specific whole-
grain intakes have been suggested [34] whereas no bio-
markers of refined grains have been described.
The aim of the present review is to provide an updated
overview of potential biomarkers of different cereals, in-
cluding different species, whole grains, refined grains as
well as specific grain fractions.
Literature search
The reviewing process conducted made use of all ele-
ments of the PRISMA statement [35] that were relevant
for a search for literature on cereal biomarkers. In brief,
original research papers and reviews were searched in at
least two databases, such as CAB Abstracts, Scopus, and
ISI Web of Knowledge using combinations of the
grouped search terms (biomarker* OR marker* OR me-
tabolite* OR biokinetics OR biotransformation OR me-
tabolism) AND (trial OR experiment OR study OR
intervention) AND (human* OR men OR women OR
patient* OR volunteer* OR participant) AND (urine OR
plasma OR serum OR blood OR excretion) AND (intake
OR meal or diet OR ingestion OR consumption OR eat-
ing OR drink* OR administration) AND (wheat* OR rye
OR oat* OR barley OR rice OR sorghum OR corn OR
maize OR germ OR endosperm OR bran OR wholegrain
OR whole-grain OR “whole grain” OR bread* OR cereal*
OR flour* OR pasta*). The research was limited to papers
in the English language, while no restriction was applied
for the publication date. The research papers with identifi-
cation or use of potential biomarkers of cereal intake were
selected by one or more skilled researchers from the list of
retrieved references in a process outlined in Fig. 1. Add-
itional papers were identified from reference lists in these
papers and from reviews or book chapters identified
through the search. For each potential biomarker identi-
fied an additional search was conducted with (“the name
and synonyms of the compound” OR “the name and syno-
nyms of any parent compound”) AND (biomarker* OR
marker* OR metabolite* OR biokinetics OR biotransform-
ation) in order to identify potential other foods containing
the biomarker or its precursor. In this second step,
PubMed, Scifinder, and Google Scholar were also used as
search platforms, along with the databases listed above.
This second search was used to evaluate the apparent spe-
cificity of proposed biomarkers. The literature search was
conducted in 2016 and papers published until the end of
2016 were included. A complementary search was con-
ducted in a similar way and additional papers published
until June 2018 were added to the literature list.
Classification of cereal biomarkers
Dietary biomarkers may reflect intake or efficacy, de-
pending on whether the biomarker is a compound
resulting from the consumed dietary item, or if it is an
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endogenous metabolite reflecting the change in the host
metabolic homeostasis evoked by the diet. A compre-
hensive classification system [36] and a validation
scheme for biomarkers of food intake (BFI) has recently
been developed by the FoodBall consortium [37]. In this
classification, biomarkers were divided into six classes:
food compound intake biomarkers (FCIBs), biomarkers
of food or food component intake (BFI), dietary pattern
biomarkers (DPBs), food compound status biomarkers
(FCSBs), effect biomarkers, and physiological or health
state biomarkers. According to the traditional classifica-
tion of dietary biomarkers, FIBs can be classified as re-
covery and concentration biomarkers depending on their
characteristic. In the FoodBall classification system, the
recovery biomarkers are included in the health state bio-
markers. Recovery biomarkers reflect the balance between
intake and excretion of a specific chemical component on
an absolute scale over a specific time period whereas con-
centration biomarkers are correlated with intake [38]. Re-
covery biomarkers represent the best standard and can be
used to calibrate other dietary instruments [39]. Some-
times prediction biomarkers are mentioned as a third cat-
egory, falling in between the recovery biomarkers and
concentration biomarkers [40]. Most biomarkers belong
to concentration biomarkers [41].
Targeted and untargeted metabolomics approaches for
discovery of cereal biomarkers
Following recent advances over the last years, metabolo-
mics has become a fundamental tool to study changes in
molecular phenotype caused by molecules inherent to
different exposures, including diet, and their interaction
with host risk of disease or other outcomes [42, 43].
Generally speaking, biomarkers may be discovered in
different sample matrices such as plasma, erythrocytes,
urine, adipose tissue, hair, and nail clippings. Each
matrix has their challenges, but in general, dietary bio-
markers are typically present at lower concentrations in
plasma compared with urine, to which many biomarker
molecules or metabolites thereof are excreted. Only a
few biomarkers are accumulated in adipose tissue and
can be detected in hair. For cereals, individual bio-
markers that reflect specific cereal foods have been de-
tected in plasma, urine, and adipose tissues and by
utilizing chemometric, multivariate tools, there are new
possibilities to use combinations of several biomarkers,
i.e., biomarker panels, which may improve prediction of
outcomes as well as monitoring of compliance or meas-
uring food intake compared with single concentration
biomarker [44].
Metabolomics methodologies can be divided into tar-
geted and untargeted approaches [45]. In targeted meta-
bolomics, a defined set of well-characterized and
annotated metabolites are analyzed typically in quantita-
tive platforms such as triple quadrupole mass spectrom-
etry (QQQ-MS) utilizing pure chemicals as standards.
Targeted metabolite analyses have been used to analyze
compounds known or suspected to be putative bio-
markers of specific foods, such as odd-numbered alkylre-
sorcinols (whole-grain wheat and rye) [46], even-
Fig. 1 Flow diagram of study selection
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numbered alkylresorcinols (quinoa) [47], avenanthra-
mides and avenacosides (oats) [48, 49]. In contrast,
untargeted approaches aim at maximizing the metabolite
coverage in a set of biological samples, even though the
vast majority of measured metabolic features remain un-
identified. A common analytical platform for profiling
assays is quadrupole time-of-flight mass spectrometry
(QTOF-MS) hyphenated with chromatographic separ-
ation in either liquid or gas phase or by NMR, but so
far, we are unaware of any study that has used such ap-
proach to discover biomarkers of cereal intake. Metabol-
ite features of special interest are then annotated/
identified at a later stage in the analytical pipeline. Inher-
ent to the wide coverage, untargeted approaches are well
suited for exploratory biomarker studies, and this ap-
proach has been used to mine for dietary exposure bio-
markers reflecting total or specific whole-grain intake as
well as specific grain-based foods after controlled inter-
ventions with specific foods or reported food intakes
[50–53]. Targeted and untargeted approaches are com-
plementary to each other and could both be useful to
discover and validate dietary biomarkers. A typical work-
flow involves identification of putative biomarker candi-
dates via an untargeted profiling approach followed by
validation of the biomarkers in targeted, quantitative
analyses applied preferentially in other study cohorts.
Recently, Zhu et al. [54] combined untargeted and tar-
geted metabolomics approaches to discover biomarkers
of whole-grain wheat intake in urine samples after intake
of whole-grain wheat bread vs refined wheat bread in a
kinetic study in 12 subjects. A panel of urinary markers
consisting of seven alkylresorcinol metabolites and five
benzoxazinoid derivatives as specific biomarkers, along
with five phenolic acid derivatives were suggested to re-
flect whole-grain wheat intake. Panels of biomarkers of
whole grain, refined grain, or fractions of specific grains
appear promising but remain to be evaluated in larger
studies.
Biomarkers of whole grains, cereal fractions, and specific
foods
To date, only a few specific biomarkers have been sug-
gested for different whole grains, bran fractions, or foods
thereof and currently no biomarkers have been sug-
gested for refined grains (Table 1). We are not aware of
any compounds that specifically reflect total whole-grain
intake from all cereals but a few compounds that are ex-
clusively found in specific whole grains or fractions of
specific grains do exist. For example, avenanthramides
are only found in oats among cereals and odd-numbered
alkylresorcinols are present in wheat, rye, and barley,
with specific homolog profiles for the different grains
mentioned. The concentrations of these molecules or
their metabolites in plasma and urine have been
suggested and used as biomarkers of intake (Table 1).
Moreover, specific benzoxazinoids and their metabolites
in plasma and/or urine have already been shown to be
specific to wheat and rye (Table 1). In some cases, mole-
cules that discriminate high vs low whole grain or bran
intake vs refined grain after controlled or reported intake
have been discovered in plasma and/or urine as metabo-
lites, but they appear not to be specific. For example, dif-
ferent cinnamic acids such as ferulic acid derivatives are
abundant in plasma and urine after wheat and rye bran
consumption (Table 1). These molecules are found in
high contents, mainly bound to the dietary fiber complex
primarily in the bran, but are liberated by microbiota in
the large intestine and absorbed [81, 91, 92]. They are
not unique to any particular grain, they will appear as
plasma biomarkers that differentiate between high vs
low consumers of whole grain or wheat bran and rye
consumers. Since these molecules are present in various
other foods and, therefore, not specific to whole-grain
intake, they are of limited use as specific dietary
biomarkers.
Alkylresorcinols and their metabolites—biomarkers of
whole-grain wheat and rye intake
Alkylresorcinols comprise a group of phenolic lipids that
have been suggested and evaluated as specific bio-
markers of wheat and rye intake [100]. They are also
found in small amounts in barley [46]. Alkylresorcinols
are located in the waxy cuticula in between the seed and
fruit coats of wheat and rye and are therefore a specific
biomarker of bran from these cereals in studies where
other whole grains are not consumed [100]. However,
bran per se is not often consumed but is usually con-
sumed as whole grain. A large number of studies have
been undertaken to evaluate alkylresorcinols as bio-
markers after self-reported intake or controlled dietary
interventions with different whole-grain wheat and rye
products (Table 1). The results suggest that alkylresorci-
nols can be used as biomarkers of whole-grain wheat
and rye, irrespective of food in what food matrix they
are present in [19, 29, 32].
Also, alkylresorcinol metabolites in urine and plasma
have been suggested to reflect the intake of whole-grain
wheat and rye [101, 102]. Due to their unique presence
in the outer parts of wheat and rye grains, alkylresorci-
nols (AR) are present not only in bran, but also in whole
grain (due to the presence of bran), but only in minute
amounts in refined flour [100]. Since alkylresorcinols are
not degraded in food processing, they will appear in
quantities related to the amount of specific whole grain
and bran consumed.
The sum of dominant alkylresorcinol homologs with
alkyl-chains in the range 17–25 carbon atoms in plasma,
i.e., total plasma alkylresorcinol concentration, reflects
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Table 1 Studies reporting candidate biomarkers for cereal food intake
Discriminating
metabolites/candidate
biomarkers
Dietary factor Study design Number
of
subjects
Analytical
method
Sample type Primary
reference(s)
Biomarkers of total whole grain (WG) intake
Total ARs WG products
RG products
Intervention study, crossover,
randomized (6 weeks)
30 GC-MS Plasma [30]
ARs WG cereal Observational study 33 GC-MS Plasma [55]
ARs WG products
RG products
Intervention study, parallel,
randomized (12 weeks)
50 LC-MS/MS Plasma [56]
ARs WG diet
RG diet
Intervention study, crossover,
randomized (6 weeks)
33 LC-MS/MS Plasma [57]
AR WG products
WG rye
WG bread
Observational study 522 GC-MS Plasma [58]
ARs
Betaine
WG diet
RG diet
Intervention study, crossover,
randomized (2 weeks)
17 GC-MS/
MS (ARs)
LC-MS/MS
(betaine)
Plasma [59]
Total ARs (C17:0, C19:0,
C21:0, C23:0, C25:0)
WG products
Habitual diet
Intervention study, parallel,
randomized (16 weeks)
316 GC-MS Plasma [31]
Total AR
AR (C17:0-C25:0)
WG products Observational study 360 GC-MS Plasma [60]
AR (C17:0, C19:0, C21:0,
C23:0, C25:0)
WG products Observational study 407 LC-MS Plasma [61]
AR (C17:0-C25:0) WG products Observational study 20 GC–MS Adipose tissue [62]
DHBA
DHPPA
DHBA+DHPPA
WG products
Cereal fiber
Observational study 104 GC-MS Urine [63]
DHBA
DHPPA
Total metabolites
WG foods
Cereal fiber
Observational study 66 GC-MS Urine [64]
DHBA
DHPPA
WG products
Fiber
Observational study 2833 HPLC Plasma [65]
DHPPA WG products
WG rye and wheat
Observational study 100 HPLC-
CEAD
Urine [66]
2-Aminophenol-Slf
HPAA-GlcA
HHPAA
HMBOA-GlcA
HBOA glycoside
HPPA
HMBOA
DHPPA-GlcA
3,5-
Dihydroxyphenylethanol-
Slf
DHPPTA-Slf
Hydroxybenzoic acid-Slf
Dihydroferulic acid-Slf
Enterolactone-GlcA
Pyrraline
3-Indolecarboxylic acid-
GlcA
Riboflavin
N-α-Acetylcitrulline
2,8-Dihydroxyquinoline-
GlcA
White bread
WG bread
Observational study 155 HPLC-q-
TOF-MS
Urine [67]
5-Nonadecyl-1,3-
benzenediol-GlcA (AR)
5-(16-Heneicosenyl)-1,3-
WG products, fatty fish and
bilberries diet
WG diet
Intervention study, parallel,
randomized (12 weeks)
106 UHPLC-q-
TOF-MS
Plasma [53]
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Table 1 Studies reporting candidate biomarkers for cereal food intake (Continued)
Discriminating
metabolites/candidate
biomarkers
Dietary factor Study design Number
of
subjects
Analytical
method
Sample type Primary
reference(s)
benzenediol-GlcA Refined wheat bread diet
Proline
Ornithine
Arginine
Grain protein-based diet (wheat,
bran, rice, and maize)
Dairy protein-based diet (milk
and milk products, yogurt and
cheese)
Meat protein-based diet (pork,
beef, and chicken)
Intervention study, crossover,
randomized (1 week)
100 LC-
tripleQ-
MS
Plasma [68]
Biomarkers of whole-grain wheat and rye intake
Total ARs WG rye bread and WG wheat
bread
Gluten-free diet
Intervention study, parallel (2
weeks)
9 GC-MS Plasma and
erythrocyte
membranes
[69]
Total ARs WG rye and wheat
Cereal fiber
Observational study 51 GC-MS Plasma [70]
Total ARs
AR C17:0, C19:0, C21:0,
C23:0, C25:0
Enterolactone
Rye bread
Wheat bread
Intervention study, crossover,
randomized (8 weeks)
39 GC-MS Plasma [71]
Total AR (C17:0, C19:0,
C21:0, C23:0, C25:0)
AR C17:0/C21:0
Enterolactone
WG wheat
WG rye crisp bread
Intervention study, crossover,
randomized (1 week)
15 GC-MS Plasma (AR)
erythrocyete
membrane (AR)
Lipoproteins (AR)
Serum
(enterolactone)
[69]
Total ARs (C17:0–C25:0)
AR C17:0/C21:0
Nordic diet (rich in WG rye and
wheat)
Control diet
Intervention study, parallel,
randomized (18–24 weeks)
158 GC-MS Plasma [32]
Total ARs
AR C17:0/C21:0
WG wheat
RG wheat
Intervention study, parallel,
randomized (12 weeks)
72 LC-MS/MS Plasma [72]
DHBA
DHPPA
Rye bread
Bread fiber
Observational study 122 HPLC-
CEAD
Urine
Plasma
[73]
DHBA
DHPPA
Rye bread with plant sterols
Rye bread
Intervention study, parallel,
randomized (4 weeks)
68 HPLC-
CEAD
Plasma [74]
DHBA
DHPPA
Rye bread Intervention study
(postprandial trial)
15 HPLC-
CEAD
Urine [75]
DHBA
DHPPA
Rye bread Intervention study
(postprandial trial)
15 HPLC-
CEAD
Plasma [76]
DHBA
DHPPA
Rye Observational study 60 HPLC-
CEAD
Urine
Plasma
[77]
DHBA
DHPPA
WG rye and wheat Observational study 52 GC-MS Urine [78]
DHBA
DHBA glycine
DHPPA
DHPPTA
RG wheat bread, WG wheat
bread
Intervention study
(postprandial trial)
12 LC-MS
HPLC-
CEAD
Urine [79]
HHPAA-GlcA
HHPAA-Slf
HPAA-Slf
HBOA-GlcA
Phenylacetylglutamine
derivative
Creatinine
N-feruloylglycine-Slf
WG rye foods Intervention study (8 weeks) 33 FIE-MS Urine [80]
DHFA
Ferulic acid
WG wheat products
Refined wheat products
Intervention study, parallel,
randomized (8 weeks)
80 HPLC-MS/
MS
Urine
Serum
Feces
[81]
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Table 1 Studies reporting candidate biomarkers for cereal food intake (Continued)
Discriminating
metabolites/candidate
biomarkers
Dietary factor Study design Number
of
subjects
Analytical
method
Sample type Primary
reference(s)
3,5-
Dihydroxyhydrocinamic
acid sulfate
Ascorbic acid
2-Aminophenol-Slf
Nonanedioic acid
DHPPA-GlcA
Indolylacryloylglycine
Enterolactone-GlcA
DHPPA-Slf
Ferulic acid-4-Slf
2,4-Dihydroxy-1,4-
benzoxazin-3-one-Slf
3,5-
Dihydroxyphenylethanol-
Slf
1,3,4,5-
Tetrahydroxycyclohexane-
1-carboxylic acid
Others non-identified
metabolites
WG rye bread
Refined wheat bread
Intervention study, crossover,
randomized (4 weeks)
20 UPLC-q-
TOF-MS
Urine [50]
Biomarkers of specific fractions of foods of wheat and rye intake
Total ARs
AR (C17:0, C19:0, C21:0,
C23:0, C25:0)
WG grains
Cereal fiber
Bran
Total fiber
Legume fiber
Observational study 165 GC-MS Plasma [82]
Total ARs
AR C17:0/C21:0
Cereal fiber Observational study 2845 GC-MS Plasma [83]
Total ARs
AR C17:0/C21:0
Cereal fiber Observational study 2744 GC-MS Plasma [84]
Total AR
AR C17:0/C21:0
Rye WG/bran
Refined wheat
Intervention study, crossover,
randomized (6 weeks)
17 GC-MS Plasma [85]
AR C23:0
AR C25:0
AR C17:0/C21:0
Rye bran flakes Intervention study
(postprandial trial)
6 GC-MS Plasma [86]
ARs (plasma)
DHBA (urine)
DHPPA (urine)
Cereal fiber Observational study 56 HPLC-
CEAD
Urine
Plasma
[87]
DHBA
DHPPA
Cereal fiber Observational study 56 HPLC-
CEAD
Plasma [88]
HPAA-Slf
HHPAA-Slf
WG sourdough rye bread
White bread with native
unprocessed rye bran
White bread with bioprocessed
rye bran
White bread
Intervention study, crossover,
randomized (postprandial
trial)
12 LC-q-TOF-
MS
Plasma [52]
2,6-dihydroxybenzoic
acid
2-aminophenol-Slf
High fiber diet
Low fiber diet
Intervention study, crossover,
randomized (5 weeks)
25 UPLC-q-
TOF-MS
Plasma [89]
Ferulic acid Rye bran bread
Inert wheat bran
Intervention study, crossover,
randomized (6 weeks)
18 HPLC Urine [90]
Ferulic acid
Vanillic acid
Sinapic acid
3,4-Dimethoxybenzoic
acid
Phenylpropionic acid
3-Hydroxyphenylpropionic
acid
Whole wheat bread with
bioprocessed bran
Whole wheat bread with native
bran
Intervention study, crossover,
randomized (postprandial
trial)
8 GCxGC-q-
TOF-MS
Urine
Plasma
[91]
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total whole-grain wheat and rye intake in a dose-
dependent manner [85]. The alkylresorcinol homolog
profile is specific for common wheat, durum wheat, and
rye, and the ratio of two specific alkylresorcinol homo-
logs (C17:0/C21:0) can be used as a biomarker of the in-
take of whole-grain rye to whole-grain wheat intake,
since the ratio is always 1.0 in whole-grain rye-based
foods, 0.1 in common wheat and 0.01 in durum wheat
[30, 31, 71, 85, 103, 104]. Plasma alkylresorcinols have a
rather short apparent elimination half-life (4–6 h) and
thus reflect medium- to long-term whole-grain wheat
and rye intake in populations with stable and frequent
intake [29, 105] but are less suitable in populations
where intake is less frequent [82, 106].
Alkylresorcinols are metabolized by CYP450-
dependent metabolism, which causes insertion of an
OH-group at the end of the alkyl-chain, followed by
subsequent oxidation into a COOH-group. This deriva-
tive then undergoes beta-oxidation, where the side-chain
is degraded by stepwise removal of C2H5 per cycle, gen-
erating free and conjugated 1,3-dihydroxy-benzoic acid
(DHBA) and 3-(1,3-dihydroxyphenyl)-1-propionic acid
(DHPPA) as the main end products [102]. Urinary ex-
cretion of DHBA and DHPPA has been shown similar
validity as plasma AR concentrations in free-living sub-
jects with high and frequent intake [64, 87]. As expected,
spot urine samples fluctuated more day to day and were
somewhat less correlated with estimated intake com-
pared with 24-h collections [63, 64, 66]. Some studies re-
port that DHBA and DHPPA are also present in urine
after intake of food compounds not derived from cereals
[34]. This could have implications for the use of DHBA
and DHPPA as biomarkers of whole-grain wheat and rye
intake, particularly in populations with low intake.
Table 1 Studies reporting candidate biomarkers for cereal food intake (Continued)
Discriminating
metabolites/candidate
biomarkers
Dietary factor Study design Number
of
subjects
Analytical
method
Sample type Primary
reference(s)
Ferulic acid
Sinapic acid
White wheat bread with
bioprocessed rye bran
White wheat bread with native
rye bran
Intervention study, crossover,
randomized (postprandial
trial)
15 GC-MS Urine [92]
Indole-2-carboxylic acid
Hydrocinnamic acid
α-tocopherol
Benzoic acid
Cycloartenol
Pantothenic acid
Phenylacetic acid
β-sitosterol
Heat-stabilized rice bran Intervention study, parallel,
randomized (4 weeks)
7 GC-MS Feces [93]
Biomarkers of quinoa
Even-numbered AR Quinoa Intervention study NS LC-MS/MS
GC-MS/
MS
Plasma [94]
Biomarkers dependent on gut microbiota
Enterolactone High-fiber bread
Fiber
Fruits and berries
Observational study 1099 TRFIA Plasma [95]
Enterolactone WG products Observational study 1889 TRFIA Plasma [95]
Enterolactone High-fiber rye
High-fiber wheat
Low-fiber foods
Intervention study, crossover,
randomized (4 weeks)
28 TRFIA Plasma [96]
Enterodiol WG diet
RG diet
Intervention study, crossover,
randomized (12 weeks)
13 HPLC-
CEAD)
Urine [97]
Enterolactone
Enterodiol
Quinoa flakes
Corn flakes
Intervention study, parallel,
randomized (4 weeks)
35 HPLC Urine
Serum
[98]
Enterodiol (serum)
Enterolactone (serum &
urine)
Flaxseed
Rice
Intervention study, parallel (6
weeks)
27 HPLC Urine
Serum
[99]
Abbreviations: AR alkylresorcinols, CEAD coulometric electrode array detection, DHBA 3,5-dihydroxy-benzoic acid, DHBA glycine 2-(3,5-dihydroxybenzamido)acetic
acid, DHFA dihydroferulic acid, DHPPA 3-(3,5-dihydroxyphenyl)-1-propanoic acid, DHPPTA 5-(3,5-dihydroxyphenyl)pentanoic acid, FIE flow infusion electrospray-
ionization, GC gas chromatography, GCxGC two-dimensional GC, GlcA glucuronide, HBOA 2-Hydroxy-1,4-benzoxazin-3-one, HHPAA 2-hydroxy-N-(2-hydroxyphenyl)
acetamide, HPAA N-(2-hydroxyphenyl) acetamide, HPLC high-performance liquid chromatography, LC liquid chromatography, MS mass spectrometry, MS/MS
tandem mass spectrometry, NS not specified, q-TOF quadrupole time-of-flight, RG refined-grain, Slf sulfate, TRFIA time-resolved fluoroimmunoassay,
WG whole-grain
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However, intakes have been correlated with levels of
DHBA and DHPPA in urine from the US population
where the intake of whole grain is small [63].
Recently, new alkylresorcinol metabolites (DHBA-gly-
cine, DHPPTA, DHCA) were detected in urine from
mice and/or humans and their half-lives were suggested
to be longer than that of previously identified alkylresor-
cinol metabolites [50, 79, 101]. These biomarkers were
evaluated in free-living Swedish men and women and re-
sults showed that DHPPTA and DHCA determined in
single 24-h urine excretions had excellent reproducibility
(ICC = 0.63 for both) and good relative validity (r = 0.40–
0.65), and thus could be useful as long-term biomarkers
of whole-grain wheat and rye intake [102]. However, 24-
h urine collections are typically not available in large
scale epidemiologic studies, but spot urine samples may
be more readily available. It is therefore highly relevant
to asses if these biomarkers analyzed in spot urine sam-
ples remain useful as biomarkers of wheat/rye whole-
grain intake [63, 107].
Benzoxazinoids—potential biomarkers of whole-grain
wheat and rye as well as for sourdough rye
Benzoxazinoids is another group of compounds that
comprise specific derivatives almost exclusively found in
wheat and rye grains. These compounds have been ori-
ginally described in the context of the defense mechan-
ism of certain plant species including rye, wheat, and
maize [108]. Nowadays, they are studied as part of the
dietary compound repertoire related in particular to
whole-grain wheat and rye. Dihm et al. [109] conducted
a detailed study where major benzoxazinoid compounds
were quantified in various grain-based products namely
commercial flours (whole-grain wheat flour, coarse-rye
flour, fine-rye flour, refined-wheat flour, graham flour,
quinoa flour, teff flour) and 20 commercial breads from
Scandinavia, as well as 3 traditionally home-baked
breads. The highest amount of benzoxazinoid com-
pounds were found in flour from fine-rye flour (3.6 mg/g
dry weight), whereas two Finnish rye breads had the
highest amount among the bread products (2.3–3.3 mg/
g dry weight). In all cases, the double-hexose conjugated
2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) was the
main benzoxazinoid metabolite.
The concentrations of specific benzoxazinoids and
their metabolites in biofluids are largely affected by fac-
tors other than the whole-grain content, such as pro-
cessing. For example, the double-hexose conjugated
compounds abundant in flour are easily degraded during
sourdough fermentation [110]. Interestingly, in the study
by Dihm et al., [109] the level of double-hexose conju-
gated forms of benzoxazinoids was very high in two
commercial Finnish breads, which further highlights the
fact that the processing method can remarkably affect
the chemical composition and dietary intake thereafter
[108]. Few studies have investigated the concentration of
benzoxazinoids in plasma and urine samples after
whole-grain consumption (Table 1). Hanhineva et al.
showed modest correlations between estimated whole-
grain rye intake and benzoxazinoid in 24-h urine, but
the levels were found to fluctuate extensively over a
period of 2-3 months [51]. Other studies have shown in-
creased plasma, urine, and tissue benzoxazinoid concen-
trations after intake of benzoxazinoid-rich foods from
wheat and rye [50, 52]. A particular metabolite derived
from benzoxazinoids via metabolism by the gut micro-
biota, and conjugation in the liver, is aminophenol sul-
fate. This compound has been reported in urine after
intake of various bread products. Therefore, it appears
that native benzoxazinoids present in the grains undergo
massive conformational changes during technological
processing a gut fermentation, as well as endogenous
metabolism, and the kinetics as well as particular chem-
ical conversions of the whole pathway are not yet
known. Thus, more studies are needed to evaluate the
feasibility of individual benzoxazinoids and their metab-
olites as biomarkers of WG intake.
Studies suggest that dietary benzoxazinoids are con-
verted into phenylacetamides (2-hydroxy-N-(2-hydroxy-
phenyl)acetamide (HHPAA) and N-(2-
hydroxyphenyl)acetamide (HPAA)) that are detectable in
urine and plasma after consumption of a meal rich in
whole grains [52]. Steffensen et al. investigated the con-
centration of different benzoxazinoids after intake of
benzoxazinoid-rich foods from rye (flakes, porridge, and
breads) in plasma, urine, and in prostate tissue in men
with prostate cancer [111]. The overall finding was that
benzoxazinoids increased in all matrices after high-
benzoxazinoid-based rye foods, but different forms dom-
inated in different matrices and varied between subjects.
Beckmann et al. [80] used flow infusion electrospray
mass spectrometry (MS) to profile metabolites in urine
from participants who reported high intakes of rye
flakes, rye pasta, or total whole-grain rye products, but
they could not find any discriminative metabolites com-
pared with subjects wash-out samples. However, they
observed discrimination in urine samples from partici-
pants who reported high whole-grain sourdough rye
bread consumption. They found that benzoxazinoid lac-
tam 2-hydroxy-1,4-benzoxazin-3-one and hydroxylated
phenyl acetamide derivatives were higher after sour-
dough rye bread consumption and that these molecules
may be candidate biomarkers of such foods. However, as
noted by Hanhineva et al. [52], bioprocessing such as
baking that involves microbial metabolism (e.g., sour-
dough fermentation) has a central role in modulating
the phytochemical content in whole-grain and bran-rich
breads and it is likely that differences in the processes
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and inclusion of different starters etc. may cause vari-
ation in suggested biomarkers. Thus, biomarkers that
may be valid for one type of product may not be univer-
sal to all.
Only very few studies have investigated whether ben-
zoxazinoids or their metabolites could be used as bio-
markers of whole-grain wheat and rye intake or for
specific foods, such as sourdough-fermented rye bread.
In one study, their levels in urine samples were well cor-
related with estimated whole-grain rye intake [53], but
they were found to fluctuate considerably in urine sam-
ples taken 2−3 months in between, probably due to short
half-lives. Further studies are needed to validate benzox-
azinoids as biomarkers in both controlled feeding-trials
and in observational studies. Correlations with estimated
intakes as well as stability over time need to be esti-
mated to assess their usefulness as biomarkers. Indeed,
the involvement of the gut microbiota in benzoxazinoids
metabolism necessitates further study to establish which
microorganisms or groups of microorganisms may be in-
volved. Recent observations that certain metabotypes
(e.g., urolithin metabotypes) determined by gut micro-
biota metabolism of other polyphenols may not be stable
over time but change with age, habitual dietary intake,
obesity, disease state, etc. suggest that gut microbiota
community structure and metabolic output are closely
linked but not fixed for a given individual [112]. This
also has implications for the validity of small phenolic
acids as biomarkers of intake, if their production from
benzoxazinoids for example, changes as gut microbiota
composition changes. Similarly, since we still know little
about how specific polyphenol-derived small phenolic
acids impact human physiology, the significance of pli-
able metabotypes in terms of human health remains to
be determined.
Biomarkers of whole-grain oat intake
Until recently, there have been no biomarker candidates
of whole-grain oat intake. Oats contains two classes of
unique compounds: avenanthramides (AVAs) and ster-
oidal saponins. AVAs are substituted N-cinnamoylan-
thranilic acids consisting of anthranilic acid and
cinnamic acid moieties. To date, 25 AVAs which differ
in the substitution patterns of two moieties have been
identified in oats; some at very low concentrations [113].
The most common avenanthramides are AVA-A (2p),
AVA-B (2f), and AVA-C (2c) and differ only by a single
moiety on the hydroxycinnamic acid ring. Several studies
have evaluated the uptake of avenanthramides in
humans and these studies found that different avenan-
thramides show different, but consistently low, bioavail-
ability in humans. Chen et al. [114] reported that serum
levels of AVA 2p, 2f, and 2c reach a peak 2 h after con-
sumption of an AVA-enriched mixture (AEM) with a
gradual return to base-line within 10 h. Recently, Zhang
et al. [115] showed for the first time that AVAs were
bioavailable in humans, after consumption of cookies
based on regular oat flour. Previous studies had used
AVA-enriched fractions or extracts [115]. AVA-B has
the slowest elimination rate and the longest half-life
compared to AVA-A and AVA-C. The half-lives were in
the range 2–5 hours [116]. AVAs like other phenolic
compounds are extensively metabolized. Walsh et al.
[116] fed 12 subjects with muffins with oat bran
enriched in AVA and investigated potential metabolites
of AVAs in plasma. They identified two methylated
AVAs but did not detect any sulfate- or glucuronide
conjugates.
Schär et al. [117] studied the excretion of phenolic
acids and avenanthramides in urine samples among
seven subjects after consumption of 60 g of oat bran
compared to a control diet low in phenolic compounds.
In total, 30 compounds were higher in urine up to 8 h
after oat bran consumption. Vanillic acid, 4- and 3-
hydroxyhippuric acids, and sulfate-conjugates of benzoic
and ferulic acids were the major compounds excreted.
Sang et al. [49] investigated whether AVAs and their
metabolites could be used as exposure markers for
whole-grain oat intake. They identified a reduction of
the double bond in the cinnamic acid unit and cleavage
of the amide bond as the major metabolic pathways of
AVAs, that the double bond reduced metabolites (DH-
AVAs) were derived from gut microbiota. Excretion in
urine suggested that the DH-AVAs had longer half-life
and that the combination of AVAs and DH-AVAs may
better reflect long-term intake and may jointly be used
as biomarkers of whole-grain oat intake. However, not
all participants produced DH-AVAs which suggest that
microbiota is an important determinant that may need
to be taken into account. However, as with other cereals,
we still know little about which bacteria or groups of
bacteria are involved, and how their production of these
metabolites changes with age, sex, health status, or xeno-
biotic (e.g., drug) exposure.
Oat contains two unique steroid glycosides,
avenacoside-A (AVE-A) and AVE-B [113, 118]. AVE-A
and -B are present in high concentrations in oat bran
products with a total content of AVE-A and -B that var-
ies from 304 to 443.0 mg/kg [118]. To our knowledge,
only one study has been reported where the metabolic
fate of AVEs has been investigated [48]. Wang et al. ana-
lyzed AVE-A and B in urine from 12 individuals during
48 h after a single dose of oat bran and they also
assessed the potential impact of the human gut micro-
biota. The aim was to evaluate the potential of these
molecules as putative biomarkers of whole-grain oat in-
take. The concentrations of AVE-A and -B increased
rapidly after oat bran intake. The average apparent half-
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lives were 4.5 h and 6.2 for AVE-A and -B, respectively.
Deglycosylation was identified as the major metabolic
path for AVE-A and -B metabolism in experiments
where pure AVE-A and -B were incubated with human
fecal samples. Both human and mice gut microbiota me-
tabolized AVE-A and -B in a similar way and 3 metabo-
lites of AVE-A and 5 metabolites of AVE-B were
detected from both man and mice [48]. The total 24-h
urinary recovery of AVE-A and -B was <5% of ingested
dose. The influence of gut microbiota on AVE-A and -B
may affect their validity as biomarkers, but further stud-
ies need to be conducted to evaluate this.
Both avenanthramides, avenacosides, and their metab-
olites may have potential as short-to-medium-term bio-
markers of oat intake, since they are not found in other
commonly consumed foods. However, they show low
bioavailability and rapid metabolism which is partly
dependent on gut microbiota. This probably affects their
potential as biomarkers of oat intake, but validation
studies are needed to confirm biomarker status [34].
Biomarkers of quinoa intake
Quinoa is a pseudocereal typically grown in the Andes,
but consumption is expanding especially in Europe
mainly because of its nutritional profile and its use as a
gluten-free alternative to cereal grains. Moreover, quinoa
is not short in lysine, which increases the bioavailability
of its amino acids, and could increase the nutritional
value of gluten-free diets [119, 120]. Recently, Ross et al.
discovered and profiled alkylresorcinols in 17 commer-
cial samples of quinoa [47]. Interestingly, the authors
found a surprising AR profile in quinoa samples, with
about 30 alkylresorcinol derivatives including odd-,
even-, and branched-chain alkylresorcinols as well as
methyl-alkylresorcinols. The total AR contents in the
quinoa samples were 58 ± 16 μg/g (AR), 182 ± 52 μg/g
(branched-chain alkylresorcinols) and 136 ± 40 μg/g (me-
thyl-alkylresorcinols) [47]. These values were much
lower than those reported in rye and wheat but in a
similar magnitude as those quantified in barley [121].
Some of the alkylresorcinol homologs in quinoa are also
present in other cereal species but the unique alkylresor-
cinol homolog composition profile with even-numbered
alkylresorcinol homologs in quinoa allows its discrimin-
ation from those alkylresorcinol derived from wheat, rye,
and barley [122]. It should be noted that some of the
compounds were identified for the first time in nature.
Among the even-numbered alkylresorcinol homologs,
C18:0, C20:0, C22:0, and C24:0 are commonly present in
quinoa but not in other cereals [47]. In order to evaluate
whether even-numbered alkylresorcinols in plasma could
be used as biomarkers of quinoa intake, Ross et al. [47]
applied a liquid chromatography tandem mass spec-
trometry (LC-MS/MS) method to identify and quantify
the even-chained alkylresorcinols in plasma from a vol-
unteer 12 h after consuming 100 g (uncooked weight) of
white quinoa. The authors showed that the concentra-
tions of these metabolites were higher in plasma after
quinoa consumption. Alkylresorcinol C22:0 had previ-
ously been described in volunteers following a crossover
intervention with a gluten-free diet, possibly due to qui-
noa intake [122]. In conclusion, since quinoa appears to
be an exclusive source of the even-chain alkylresorcinols
and because these compounds have been detected and
quantified in plasma samples following quinoa intake, it
is feasible to propose these compounds as biomarkers of
quinoa intake. However, validation studies to assess half-
life, dose response, reproducibility, and validity under
controlled intake and under free-living condition are
needed.
Biomarkers of rice intake
Very few studies have been reported where putative bio-
markers of rice intake were explored. Guertin et al.
[123], analyzed baseline serum samples from 502 partici-
pants in the Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial with LC-MS/MS and
gas chromatography mass spectrometry (GC-MS). They
detected 412 known metabolites and correlated these to
different food intakes, reported by FFQ, including rice
intake. Among investigated metabolites, only docosahex-
aenoic acid (DHA) correlated significantly with rice in-
take, and this was likely due to confounding by fish
intake. Li et al. [124] analyzed the plasma metabolome
in 38 children after 4-week intake of rice bran in one
arm of a study to investigate its impact on cholesterol
concentrations in plasma. The authors analyzed 854 me-
tabolites in plasma and about 300 were also found in the
rice bran food metabolome. Rice bran metabolites de-
tected with high relative abundance in plasma included
methionine sulfone, alpha-hydroxycaproate,
linoleoyllinolenoyl-glycerol, palmitoyl-linolenoylglycerol,
pyridoxal, 2-hydroxyhippurate, salicylate, gamma-
glutamylglutamate, gamma-glutamylthreonine, hypoxan-
thine, and dihydroorotate. However, it is unclear to what
extent these metabolites, separately or in combination,
would specifically reflect rice bran intake.
In another study [125], the same group applied GC-
MS-based metabolomics on stool samples from 19 colo-
rectal cancer survivors who were fed heated rice bran or
control for a period of 4 weeks. They found 39 metabo-
lites that were higher after rice bran intake compared
with baseline and which, at the same time, overlapped
with the rice bran metabolome. These metabolites in-
cluded lipid compounds, tryptophan metabolites, flavo-
noids, and B-vitamins, among other molecules. Although
the authors suggest that rice bran-derived phytochemi-
cals in plasma and stool samples may be used as
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biomarkers of rice bran intake, most metabolites are
likely too unspecific to be used as specific biomarkers of
rice bran intake. Further studies are needed to find bio-
markers or biomarker panels that are specific to rice
intake.
Biomarkers of refined grains
To our knowledge, there are currently no suggested bio-
markers of refined grain intake. This may be due to the
fact that most bioactive compounds that could be puta-
tive biomarkers are typically located in the outer parts of
the grains, and not in the starchy endosperm. The
starchy endosperm in cereals contains low amounts of
phytochemicals compared with the bran and germ [126].
Moreover, most studies that have been undertaken to
find biomarkers of whole grains have used refined grains
as a control and it is difficult to use an appropriate con-
trol for refined grains per se.
Critical factors that affect biomarker validity and
reproducibility—key features of biomarkers
Biomarker discovery needs to be followed by validation.
Several criteria need to be fulfilled before a biomarker
can be considered valid, and a framework for the valid-
ation of dietary biomarkers have been established [37].
Early validation may include assessment of how specific
a biomarker is for a specific food, its pharmacokinetics,
dose-response, and its non-dietary determinants. Validity
and reproducibility are two features that to a great ex-
tent determine the usefulness of a biomarker. Validity is
the lack of systematic measurement error when compar-
ing the actual observation with that obtained using a ref-
erence method [127]. The correlation between a
biomarker measurement and the true intake of the ex-
posure of interest reflects the validity of the biomarker,
but since true dietary exposure cannot be estimated
without measurement error, the correlation only reflects
the upper limit of the validity [128]. However, it should
be kept in mind that validity often is study-specific, and
therefore it is important to estimate the validity under
different conditions in different populations. The repro-
ducibility of a biomarker describes the correlation be-
tween samplings within the same individual on
independent occasions [38]. The biomarker reproduci-
bility is largely determined by the stability of the individ-
ual’s intake of the food/nutrient of interest and the
elimination half-life of the biomarker. A short half-life
can be compensated for by stable and continuous intake
[129]. An ideal biomarker should be both valid and re-
producible, i.e., plausible and robust and provide an ac-
curate ranking of the intake. A large number of factors
affect the accuracy of a biomarker and it is therefore im-
portant to evaluate the biomarker before it is used, in
order to estimate its reproducibility and validity and
identify the factors that affect these parameters. Most
food biomarkers fall into the category of concentration
biomarkers and the accuracy of such biomarkers are
highly variable and dependent on differences in bioavail-
ability of the biomarker substance within and between
subjects, differences in metabolism, interactions with
other dietary components, differences in distribution
volume across subjects as well as the potential impact of
gut microbiota on biomarker compounds [130]. It is
therefore important to evaluate these aspects of each
biomarker before using it as an accurate measure of the
intake.
Validation and application of cereal intake biomarkers
Only very few of the suggested biomarkers of cereal in-
take have been through rigorous validation. All putative
biomarkers covered in this review fall into the category
of food intake biomarkers and can be classified as con-
centration biomarkers [36, 38]. This means that specific
intakes are correlated with the concentrations of the bio-
markers in the biological matrix investigated and that
the biomarkers are affected by inter-personal variation
in bioavailability, absorption, metabolism, distribution,
and elimination. Moreover, gut microbiota may affect
biomarker concentration. Variation inherent to non-
dietary factors may distort the intake-biomarker rela-
tionship and it is important to establish the impact of
the different non-dietary determinants as part of the val-
idation process before using the biomarker [60]. For
most of the putative biomarkers of cereal intake, this
variation remains to be determined. In fact, most of the
suggested biomarkers have not been validated at all or
only evaluated with regard to some of the criteria [37].
Alkylresorcinols and their metabolites are rare examples
of food biomarkers that have been extensively validated
as biomarkers of whole-grain wheat and rye intake in
various matrixes (alkylresorcinols: plasma, erythrocytes,
adipose tissue biopsies; metabolites: plasma and urine)
(Table 1). Due to a short-half life (about 5 h), they
mainly reflect short-term intake, unless the whole-grain
wheat and/or rye intake is consumed consistently (> 2
times per day). Under such conditions, the concentration
is stable in fasting plasma samples. Alkylresorcinol con-
centrations in plasma and adipose tissues as well as their
metabolites in plasma and urine samples are well corre-
lated with estimated whole-grain wheat and rye intakes
with correlations in the magnitude 0.3–0.55, depending
on the used measure of dietary intake [31, 60, 63, 64,
131]. Alkylresorcinols have been found to be a useful
complement to traditional dietary assessment methods
in several endpoint studies as well as measures as com-
pliance in dietary interventions [29, 31, 82, 83]. But it re-
mains to be tested whether they can be combined with
other biomarkers to further improve their specificity and
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sensitivity. Moreover, alkylresorcinols in fecal samples
have not yet been evaluated as biomarkers. To our
knowledge, other biomarker candidates of whole grains,
refined grain or fractions of different cereals have not
yet been applied as such in endpoint studies. For candi-
date biomarkers of other grains, more fundamental val-
idation is needed.
Conclusion
Several biomarker candidates for whole-grain wheat, rye,
and oats have been discovered as well as biomarker can-
didates of fermented rye bread. These biomarker mole-
cules are uniquely found in biological samples from
humans after consumption and can be traced down to
actual compounds in the food. However, their validity
and reliability, which will affect their usefulness as bio-
marker candidates in epidemiological studies, typically
remains to be evaluated under controlled and free-living
conditions in humans. Moreover, factors that explain
within- and between-person variability in putative bio-
markers need to be studied in order to understand their
potential and limitations as specific food intake bio-
markers. Collection of comprehensive data on lifestyle,
health parameters, and OMICs-data including gut
microbiota will facilitate the dissection of sources of
inter-personal variation and improve the understanding
of what factors contribute to inter-individual variation in
the ADME of dietary biomarkers.
Metabolomics has enabled simultaneous (semi)quanti-
tation of several biomarkers at the same time in a large
number of samples. This allows multi-biomarker signa-
tures to be used as biomarkers rather than single mole-
cules. This approach may have a larger potential to
improve specificity and should be further evaluated for
different grain intakes. Future studies should evaluate
the most suitable matrix (plasma, erythrocytes, urine,
hair, nails, or adipose tissue) for determination of spe-
cific biomarkers that reflect long-term intake, which is
of highest relevance in most diet and health studies.
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